Blood cancer is often a nightmare for every person, as the prognosis of it is unfavorable. Scientists are looking for some suitable drugs which tackle the malignant tumor without causing any side effects. The University of Alberta provides some optimistic approaches to treat cancer by focusing on cell signaling systems. They have identified a compound PCLX-001 that could lead to tumor regression in mouse models.
It is derived from a drug studied for treating African sleeping sickness. It is a potent inhibitor of the enzyme NMT (N-myristoyl transferase). This protein acts as a target for drugs, as they are overexpressed in the tumor. It favors process myristoylation, by which the fatty acid myristate is added to proteins. As a result, this conjugated protein will further move to the cell membrane and involves in the cell signaling system.
After analyzing 300 different cancer cell types, they found that it was highly useful in treating blood cancer cells like lymphomas and leukemia than other cancer cell types. Also, the drug killed B-cell tumor cells in both lab-cultured cells and animal models, leaving other cells unharmed.
Phase 1 clinical trials to treat cancers with this drug is developing in Edmonton and Toronto. Since a low concentration of the PCLX-001 drug is causing damage to the cancer cell, it will have more impact on cancer therapies in the future.
Do you want to publish on Apple News, Google News, and more? Join our writing community, improve your writing skills, and be read by hundreds of thousands around the world!
Source: Medical Xpress